Company: IMRX
Filing Date: 2025-09-25
Form Type: 424B5
Source: 0001104659-25-093438
Chunk: 10

Company: Immuneering Corp
Filing Date: 2025-09-25
Form: 424B5
Chunk 10
---
 the terms of the securities purchase agreement, this offering constitutes a qualified public offering. Accordingly, pursuant to the securities purchase agreement, subject to the closing of this offering and the other conditions set forth therein, the Investor has agreed to purchase, and we have agreed to issue and sell to the Investor, an aggregate of 2,708,559 shares of Class A common stock at the closing of the concurrent private placement

Class A common stock to be outstanding after this offering and the concurrent private placement

57,655,779 shares of Class A common stock (or 60,499,766 shares if the underwriters exercise their option to purchase additional shares in full).

Use of proceeds

We estimate that our net proceeds from this offering and the concurrent private placement will be approximately $187.4 million, or approximately $212.0 million if the underwriters exercise their option to purchase additional shares in full, after deducting underwriting discounts and commissions and estimated offering expenses payable by us. We intend to use the net proceeds from this offering and the concurrent private placement to advance the preclinical and clinical development of our product candidates and for working capital and other general corporate purposes.

Risk factors

You should read the “Risk Factors” section beginning on page S-9of this prospectus supplement and the other information included in, or incorporated by reference into, this prospectus supplement for a discussion of certain factors you should carefully consider before deciding to invest in our securities.

Nasdaq Global Market 
 symbol

“IMRX”.

<div align='center'>S-7</div>

TABLE OF CONTENTS

The number of shares of our Class A common stock to be outstanding after this offering and the concurrent private placement is based on 35,987,306 shares of our Class A common stock and no shares of our Class B common stock outstanding as of June 30, 2025 and excludes:

•

8,405,371 shares of Class A common stock issuable upon exercise of stock options outstanding under our equity incentive plans as of June 30, 2025 at a weighted average exercise price of $3.78 per share;

•

937,983 shares of Class A common stock reserved for future issuance under our 2021 Incentive Award Plan as of June 30, 2025;

•

1,051,390 shares of Class A common stock reserved for future issuance under our 2021 Employee Stock Purchase Plan as of June 30, 2025;

•

382,000 shares of Class A common stock reserved for future issuance under our